<i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

“…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Several components contribute to detection of the mixture. by Majid Ghaninia (37312)

“…(A) In <i>Apis mellifera</i> omission of phenylacetaldehyde, nonanal, decanal, acetophenone, and p-anisaldehyde from the blend significantly decreased the responses elicited by the OSNs. …”

Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)

Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

“…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”

Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

“…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”

Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

“…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”

Cumulative and ruptured oocysts. by Lauren M. Childs (593877)

Local and global interpretability of NATE. by Seongil Han (20490232)

Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? by Aygul Tantik PAK (12686251)

“…The mean analgesic intake before BoNTA was 11.48±4.68 tablets/month, while it decreased to 6.53±2.72 tablets/month in the first month (p<0.001) and 5.40±2.46 tablets/month in the second month (p<0.001). …”